| 000 | 01893 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516142844.0 | ||
| 264 | 0 | _c20130801 | |
| 008 | 201308s 0 0 eng d | ||
| 022 | _a1432-0843 | ||
| 024 | 7 |
_a10.1007/s00280-013-2149-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPatnaik, Amita | |
| 245 | 0 | 0 |
_aPhase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _cJun 2013 |
||
| 300 |
_a1499-506 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCamptothecin _xadministration & dosage |
| 650 | 0 | 4 | _aData Interpretation, Statistical |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aIrinotecan |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xadministration & dosage |
| 650 | 0 | 4 |
_aProdrugs _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aPapadopoulos, Kyriakos P | |
| 700 | 1 | _aTolcher, Anthony W | |
| 700 | 1 | _aBeeram, Muralidhar | |
| 700 | 1 | _aUrien, Saïk | |
| 700 | 1 | _aSchaaf, Larry J | |
| 700 | 1 | _aTahiri, Sanaa | |
| 700 | 1 | _aBekaii-Saab, Tanios | |
| 700 | 1 | _aLokiec, François M | |
| 700 | 1 | _aRezaï, Keyvan | |
| 700 | 1 | _aBuchbinder, Aby | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 71 _gno. 6 _gp. 1499-506 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-013-2149-2 _zAvailable from publisher's website |
| 999 |
_c22628466 _d22628466 |
||